Last reviewed · How we verify

NCT05214170

Physician Acceptance of the NeuTrace System for Cardiac Electroanatomic Mapping

Status unknown NA Last updated 7 April 2023
What this trial tests

NA trial testing Electroanatomic mapping with the NeuTrace System in Arrhythmias, Cardiac in 20 participants. Status unknown.

Timeline
7 June 2021
Primary endpoint
7 May 2024
7 June 2024

Quick facts

Lead sponsorNeuTrace, Inc.
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposedevice feasibility
Enrollment20
Start date7 June 2021
Primary completion7 May 2024
Estimated completion7 June 2024
Sites1 location across Lithuania

Drugs / interventions tested

Conditions studied

Sponsor

NeuTrace, Inc.

Who can join

Adults 18 to 80, any sex, with Arrhythmias, Cardiac or Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The trial is a prospective, non-randomized, single-arm feasibility trial to evaluate physician acceptance of the NeuTrace System v1.0 for cardiac electroanatomic mapping.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Arrhythmias, Cardiac

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05214170.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing